Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949960 · ClinicalTrials.gov registry record · Phase 2
DMT210 Topical Gel in the Treatment of Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT02949960 is a Phase 2 study of Atopic Dermatitis that has completed, run by Dermata Therapeutics. The registered enrollment target is 19 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02949960, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG DMT210 Topical Gel
- DRUG Vehicle Control
Study Locations (2)
Texas
- Dermata Investigational Site - Houston
Virginia
- Dermata Investigational Site - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02949960
The ClinicalTrials.gov registry entry for NCT02949960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The listed sponsor is Dermata Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which DMT210 Topical Gel is the first listed.
NCT02949960 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT02949960 about?
NCT02949960 is a clinical study titled "DMT210 Topical Gel in the Treatment of Atopic Dermatitis". The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).
What is the current status of trial NCT02949960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-10. Estimated completion is 2017-07-14.
What conditions does trial NCT02949960 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02949960?
The interventions under investigation include: DMT210 Topical Gel (DRUG), Vehicle Control (DRUG).
Who is sponsoring clinical trial NCT02949960?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02949960 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.